Loading clinical trials...

A Pilot Study to Explore the Role of Gut Flora in Lupus | Clinical Trials | Clareo Health

WITHDRAWN

A Pilot Study to Explore the Role of Gut Flora in Lupus

NCT04213690•ProgenaBiome

Summary

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

Detailed Description

The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to Lupus.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
•a. May be signed by parent or legal guardian in the case of minor or adult unable to provide consent
•2. Male or female of all ages. (interest is given to children who present with autism or Crohn's and whose parents wish to analyze their children's gut flora. Also of interest analysis of development of the child's microbiome. In the case of autism, the younger the child, the better to correct the neurological problems if an association is found between autism and the microbiome)
•3. Diagnosis of Lupus by a physician

Exclusion Criteria

•1. Refusal to sign informed consent form
•2. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
•3. Postoperative stoma, ostomy, or ileoanal pouch
•4. Participation in any experimental drug protocol within the past 12 weeks
•5. Treatment with total parenteral nutrition

Locations (1)

ProgenaBiome

Ventura, California, United States

Key Dates

Start Date

March 2, 2020

Primary Completion Date

March 1, 2030

Completion Date

July 1, 2030

Last Updated

June 5, 2025

Conditions

Lupus ErythematosusLupus Erythematosus, Systemic

Interventions

No Intervention

OTHER

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

NCT06647069

Systemic Lupus Erythematosus (SLE)Rheumatoid Arthritis (RA)

View study

RECRUITINGPHASE2

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983

Lupus Erythematosus, SystemicLupus Nephritis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Pilot Study to Explore the Role of Gut Flora in Lupus

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus